Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesDefence Therapeutics Inc

Defence Therapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.335 CAD -0.01 ( 1.47%)
Last update at 2026-11-04T15:10:00Z
VOLUME
6050
Market Cap
29.83M

Momentum Score

…

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.32
Low
0.34
High
52 Week Price Range
0.50
Low
1.05
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Defence Therapeutics Inc is a Canada-listed clinical-stage biopharmaceutical company; public disclosures describe a platform intended to enhance targeted delivery of therapeutic agents to tumors. Long-term growth may be driven by clinical-trial progress, strategic partnerships or licensing and eventual regulatory approvals that could support commercialization. Investors may find the company attractive for potential upside if its programs achieve clinical validation and broader platform adoption.
Major investment risks include clinical and regulatory failure, limited operating history, small-market liquidity and the need for additional financing that could dilute shareholders.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.34
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-506.97%
Net Debt
1.65M
ROCE
358.52%
Diluted EPS TTM
-0.08

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax - -13.19M -6.87M -7.34M -2.86M
Net income - -13.19M -6.76M -7.34M -2.86M
Selling general administrative 1.94M 8.44M 2.71M 3.35M 1.70M
Reconciled depreciation - 0.09M 0.01M 0.00M -
Operating income - -12.82M -6.55M -7.32M -2.86M
Interest expense - 0.40M 0.26M 0.00M -
Tax provision - 0.00M -0.10M 0.00M -
Interest income - 0.02M 0.01M 0.00M -
Net interest income - -0.38M -0.26M 0.00M -
Total revenue - 0.00M 0.00M 0.00M 0.00M
Total operating expenses - 12.82M 6.55M 7.32M 2.86M
Total other income expense net - 0.00M -0.07M -0.02M -
Net income from continuing ops - -13.19M -6.76M -7.34M -2.86M
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Total assets 0.48M 3.53M 0.72M 5.61M 1.91M
Intangible assets - 0.04M 0.05M 0.05M 0.05M
Total liab 4.06M 1.97M 1.11M 0.12M 0.05M
Total stockholder equity -3.58M 1.57M -0.39M 5.49M 1.86M
Capital stock 19.24M 16.95M 9.33M 7.97M 2.40M
Retained earnings -29.81M -16.91M -10.52M -3.53M -0.67M
Cash 0.06M 2.79M 0.51M 5.45M 1.87M
Total current liabilities 4.05M 0.22M 1.11M 0.12M 0.05M
Net debt 1.65M - - - -
Short long term debt 1.71M - - - -
Total current assets 0.21M 3.43M 0.67M 5.56M 1.87M
Net receivables 0.10M 0.15M 0.03M - -
Long term debt - 1.75M - - -
Non current assets total 0.26M 0.10M 0.05M 0.05M 0.05M
Capital lease obligations 0.04M 0.00M - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Type yearly yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30 2020-06-30
Investments -0.20M -0.07M 0.00M - -0.05M
Net borrowings -0.01M 2.35M 0.00M - -
Total cash from financing activities 1.76M 10.01M 1.10M 5.88M 2.04M
Net income -13.19M -6.76M -7.34M -2.86M -0.67M
Change in cash -2.74M 2.29M -4.95M 3.59M 1.87M
Begin period cash flow 2.79M 0.51M 5.45M 1.87M 0.00M
End period cash flow 0.06M 2.79M 0.51M 5.45M 1.87M
Total cash from operating activities -4.29M -7.66M -6.04M -2.29M -0.13M
Issuance of capital stock 1.89M 8.25M 1.10M 2.76M 2.28M
Depreciation 0.09M 0.01M 0.00M - -
Dividends paid 0.00M 0.00M 0.00M - -
Capital expenditures 0.20M 0.07M 0.00M 0.00M 0.05M
Change in working capital 2.58M -1.36M 0.93M -0.04M 0.05M
Stock based compensation 5.84M 0.30M 0.37M 0.61M 0.18M
Other non cash items 0.40M 0.26M - - 0.31M
Free cash flow -4.49M -7.72M -6.04M -2.29M -0.18M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(CAD)
Price
(CAD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
DTC
Defence Therapeutics Inc		 -0.01
1.47%		 0.34 - - - 89.80 -9.99
DRUG
Bright Minds Biosciences Inc		 -10.97
29.58%		 26.11 - - - 13.50 -0.10
METX
ME Therapeutics Holdings Inc.		 -0.05
4.55%		 1.05 - - - 72.00 -
TELI
Telescope Innovations Corp.		 0.01
1.56%		 0.33 - - 4.32 6.45 -1.62
LOBE
Lobe Sciences Ltd		 -
-%		 0.04 - - 2.44 15.58 1.64

Profile*

Defence Therapeutics Inc

Defence Therapeutics Inc. develops a biological drug enhancer platform that improves the efficacy and safety of a multitude of a multitude of biological/biosimilar-based pharmaceuticals used in the treatment of cancer and infectious diseases. The company focuses on the research, development, and advancement of products using its Accum technology, including antibody drug conjugates targeting various cancers; the anti-cancer AccuTOX program, which has completed preclinical studies for solid T-cell lymphoma, breast cancer, and melanoma; the ARM-X vaccine program, a mesenchymal stem cell-based vaccine targeting cancer; and mRNA vaccination program. The company also offers Dendritic Cell (DC) cancer vaccines using Accum; a protein-based vaccine formulation against COVID and infectious diseases; and a cervical cancer vaccine. The company was formerly known as Accum Therapeutics Inc. and changed its name to Defence Therapeutics Inc. in March 2020. The company was incorporated in 2017 and is headquartered in Montreal, Canada.

7171 Rue Frederick-Banting, Montreal, QC, Canada, H4S1Z9

514 947 2272

https://defencetherapeutics.com

Name Title Year Born
Mr. Sebastien Plouffe CEO, President & Director 1972
Mr. Arnab Kumar De A.C.M.A., C.M.A., C.P.A., CGMA, M.B.A. CFO & Corporate Secretary NA
Dr. Mark Lambermon Ph.D. Head of Quality & Operations NA
Dr. Maxime Parisotto Chief Scientific Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PRL
CAD 30.50
+15.05%
DSV
CAD 11.02
+14.55%
USA
CAD 4.29
+13.19%
NUAG
CAD 7.70
+12.90%
GMIN
CAD 43.79
+12.86%
DRUG
CAD 26.11
-29.58%
HUT
CAD 68.98
-22.41%
UCU
CAD 2.09
-14.34%
VET
CAD 14.87
-14.29%
PHX
CAD 10.96
-13.56%

Equity Sectors*

  • Basic Materials

    +5.46%

  • Communication Services

    +3.38%

  • Consumer Cyclical

    +3.11%

  • Consumer Defensive

    +1.35%

  • Energy

    -4.79%

  • Financial Services

    +2.66%

  • Healthcare

    -0.72%

  • Industrials

    -0.11%

  • Real Estate

    +1.84%

  • Technology

    +1.05%

  • Utilities

    +0.39%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…